Arecor Therapeutics, Calculus portfolio company advancing today’s therapies to enable healthier lives, is pleased to announce that the European Patent Office has granted a key patent, protecting novel formulations of the Group’s proprietary insulin products, AT278 and AT247. In addition, the China National Intellectual Property Administration has granted a further patent protecting AT278 and AT247.

Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: “Our innovative Arestat™ enabled insulin products, AT278 and AT247, have the potential to address key needs in the better treatment of diabetes. AT278 is a ‘disrupter insulin’, a unique formulation which combines an ultra-rapid profile and high concentration and has potential as the gold standard insulin for the growing population of people with high daily insulin needs, as well as a key enabler for pump miniaturisation and extended wear-time. AT247 has a ‘best-in-class’ ultra-rapid pharmacokinetic profile with the potential to enable fully automated insulin delivery systems.  Diabetes is one of the leading causes of death and disability worldwide, and affects people regardless of country, age group, or sex. These additional granted patents aim to serve and protect Arecor’s innovative technologies in these important markets.”